Congress Park Capital LLC Has $217,000 Position in CytomX Therapeutics, Inc. $CTMX

Key Points

• Congress Park Capital LLC reduced its stake in CytomX Therapeutics by 85.8%, selling 578,264 shares and retaining only 95,422 shares worth approximately $217,000.
• Institutional investors now own 67.77% of CytomX Therapeutics, with notable increases in holdings from firms such as Millennium Management LLC and Acadian Asset Management LLC.
• Analysts have rated CytomX Therapeutics stocks positively, with an average rating of "Buy" and a consensus price target of $5.30, following recent coverage by firms including Oppenheimer and Barclays.

Congress Park Capital LLC decreased its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 85.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 95,422 shares of the biotechnology company's stock after selling 578,264 shares during the quarter. Congress Park Capital LLC owned 0.12% of CytomX Therapeutics worth $217,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CTMX. Northern Trust Corp increased its stake in CytomX Therapeutics by 16.0% in the fourth quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company's stock valued at $155,000 after acquiring an additional 20,746 shares during the period. Millennium Management LLC increased its stake in CytomX Therapeutics by 25.8% in the fourth quarter. Millennium Management LLC now owns 3,221,012 shares of the biotechnology company's stock valued at $3,318,000 after acquiring an additional 660,756 shares during the period. Tidal Investments LLC grew its stake in CytomX Therapeutics by 55.5% during the fourth quarter. Tidal Investments LLC now owns 382,529 shares of the biotechnology company's stock worth $394,000 after buying an additional 136,528 shares during the last quarter. Formidable Asset Management LLC grew its stake in CytomX Therapeutics by 55.5% during the fourth quarter. Formidable Asset Management LLC now owns 382,529 shares of the biotechnology company's stock worth $394,000 after buying an additional 136,528 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in CytomX Therapeutics by 18.6% during the first quarter. Assenagon Asset Management S.A. now owns 711,454 shares of the biotechnology company's stock worth $452,000 after buying an additional 111,604 shares during the last quarter. Institutional investors own 67.77% of the company's stock.

Wall Street Analysts Forecast Growth

CTMX has been the topic of several research analyst reports. Barclays initiated coverage on shares of CytomX Therapeutics in a research note on Wednesday, September 17th. They set an "overweight" rating and a $3.50 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics in a research note on Monday. They set an "overweight" rating and a $6.00 price objective on the stock. Finally, Oppenheimer initiated coverage on shares of CytomX Therapeutics in a research note on Thursday, July 31st. They set an "outperform" rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $5.42.

CytomX Therapeutics Price Performance

Shares of CTMX stock traded up $0.07 during trading hours on Tuesday, reaching $2.13. 1,991,086 shares of the company were exchanged, compared to its average volume of 3,202,000. CytomX Therapeutics, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $3.10. The stock's fifty day moving average is $2.15 and its two-hundred day moving average is $1.73. The company has a market cap of $351.92 million, a price-to-earnings ratio of 3.71 and a beta of 2.18.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.